155 related articles for article (PubMed ID: 25174682)
1. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology.
Dufresne A; Alberti L; Brahmi M; Kabani S; Philippon H; Pérol D; Blay JY
BMC Cancer; 2014 Aug; 14():632. PubMed ID: 25174682
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
3. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.
Dufresne A; Bertucci F; Penel N; Le Cesne A; Bui B; Tubiana-Hulin M; Ray-Coquard I; Cupissol D; Chevreau C; Perol D; Goncalves A; Jimenez M; Bringuier PP; Blay JY
Br J Cancer; 2010 Aug; 103(4):482-5. PubMed ID: 20664593
[TBL] [Abstract][Full Text] [Related]
4. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
Corless CL; Ballman KV; Antonescu CR; Kolesnikova V; Maki RG; Pisters PW; Blackstein ME; Blanke CD; Demetri GD; Heinrich MC; von Mehren M; Patel S; McCarter MD; Owzar K; DeMatteo RP
J Clin Oncol; 2014 May; 32(15):1563-70. PubMed ID: 24638003
[TBL] [Abstract][Full Text] [Related]
5. Prediction of desmoid tumor progression using miRNA expression profiling.
Dufresne A; Paturel M; Alberti L; Philippon H; Duc A; Decouvelaere AV; Cassier P; Blay JY
Cancer Sci; 2015 May; 106(5):650-5. PubMed ID: 25707497
[TBL] [Abstract][Full Text] [Related]
6. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)
J Clin Oncol; 2010 Mar; 28(7):1247-53. PubMed ID: 20124181
[TBL] [Abstract][Full Text] [Related]
8. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.
Zhi X; Zhou X; Wang W; Xu Z
PLoS One; 2013; 8(11):e79275. PubMed ID: 24223922
[TBL] [Abstract][Full Text] [Related]
9. Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.
Iurlo A; Gianelli U; Beghini A; Spinelli O; Orofino N; Lazzaroni F; Cambiaghi S; Intermesoli T; Rambaldi A; Cortelezzi A
Oncotarget; 2014 Jul; 5(13):4665-70. PubMed ID: 25015329
[TBL] [Abstract][Full Text] [Related]
10. Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature.
Wcislo G; Szarlej-Wcislo K; Szczylik C
J Cancer Res Clin Oncol; 2007 Aug; 133(8):533-8. PubMed ID: 17453242
[TBL] [Abstract][Full Text] [Related]
11. Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status.
Seinfeld J; Kleinschmidt-Demasters BK; Tayal S; Lillehei KO
J Neurosurg; 2006 May; 104(5):749-56. PubMed ID: 16703880
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population.
Grabellus F; Worm K; Sheu SY; Siffert W; Schmid KW; Bachmann HS
J Clin Pathol; 2011 Nov; 64(11):1021-4. PubMed ID: 21757432
[TBL] [Abstract][Full Text] [Related]
13. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
14. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors.
Skubitz KM; Manivel JC; Clohisy DR; Frolich JW
Cancer Chemother Pharmacol; 2009 Aug; 64(3):635-40. PubMed ID: 19404642
[TBL] [Abstract][Full Text] [Related]
15. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
Debiec-Rychter M; Dumez H; Judson I; Wasag B; Verweij J; Brown M; Dimitrijevic S; Sciot R; Stul M; Vranck H; Scurr M; Hagemeijer A; van Glabbeke M; van Oosterom AT;
Eur J Cancer; 2004 Mar; 40(5):689-95. PubMed ID: 15010069
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
[TBL] [Abstract][Full Text] [Related]
17. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Heinrich MC; Owzar K; Corless CL; Hollis D; Borden EC; Fletcher CD; Ryan CW; von Mehren M; Blanke CD; Rankin C; Benjamin RS; Bramwell VH; Demetri GD; Bertagnolli MM; Fletcher JA
J Clin Oncol; 2008 Nov; 26(33):5360-7. PubMed ID: 18955451
[TBL] [Abstract][Full Text] [Related]
18. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Hong JL; Li J; Li J; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
Yoo C; Ryu MH; Ryoo BY; Beck MY; Kang YK
Invest New Drugs; 2013 Oct; 31(5):1367-74. PubMed ID: 23591629
[TBL] [Abstract][Full Text] [Related]
20. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.
Al-Batran SE; Hartmann JT; Heidel F; Stoehlmacher J; Wardelmann E; Dechow C; Düx M; Izbicki JR; Kraus T; Fischer T; Jäger E
Gastric Cancer; 2007; 10(3):145-52. PubMed ID: 17922091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
